Tolimidone is under clinical development by Melior Pharmaceuticals I and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tolimidone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tolimidone overview

Tolimidone (MLR-1023) is under development for the treatment of type 2 diabetes, type 1 diabetes, non-alcoholic steatohepatitis, plumonary edema. It is a repositioned small molecule. The drug candidate is administered orally. It is developed based on the theraTRACE platform. It acts by activating Lyn Kinase. It was also under development for gastric ulcer.

It was also under development for the treatment of COVID-19 associated cytokine storm.

Melior Pharmaceuticals I overview

Melior Pharmaceuticals I is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders. The company is headquartered in Exton, Pennsylvania, the US.

For a complete picture of Tolimidone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.